MCA-205 Cells
USUSD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | MCA-205 is a murine fibrosarcoma cell line derived from C57BL/6 mice. It was originally established through methylcholanthrene-induced tumorigenesis, a classic chemical carcinogenesis approach widely used to generate transplantable tumor models in syngeneic mice. MCA-205 serves as an immunocompetent tumor model, meaning it can be implanted into immunocompetent C57BL/6 mice without rejection, making it highly suitable for preclinical studies of cancer immunotherapy and tumor immunology. Biologically, MCA-205 tumors are classified as non-immunogenic or poorly immunogenic, a characteristic that reflects their low baseline antigenicity and reduced susceptibility to spontaneous immune-mediated rejection. This feature is particularly useful for evaluating the efficacy of checkpoint blockade therapies (such as anti-PD-1 or anti-CTLA-4) or tumor vaccines under conditions that mirror the immune-evasive nature of many human cancers. Despite their poor intrinsic immunogenicity, MCA-205 tumors can respond to immune modulation when combined with radiation therapy, oncolytic viruses, or TLR agonists, making them a versatile platform for combinatorial treatment testing. MCA-205 cells grow rapidly both in vitro and in vivo, forming aggressive fibrosarcomas when injected subcutaneously. These tumors have a high degree of vascularization and support reproducible tumor growth kinetics, allowing for consistent measurement of tumor burden and treatment response. Due to their murine origin and syngeneicity with C57BL/6 mice, MCA-205 cells are not appropriate for human-specific assays but are indispensable for exploring immune mechanisms in a fully functional host immune system. |
|---|---|
| 生物體 | Mouse |
| 疾病 | Mouse fibrosarcoma |
| 同義詞 | MCA 205, MCA205 |
特徵
| 生長特性 | Adherent |
|---|
監管數據
| 引用 | MCA-205 (Cytion catalog number 305730) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 10090 |
| Cellosaurus 編號 | CVCL_VR90 |
生物分子資料
| 突變譜 |
|---|
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS and 1% NEAA |
| 解離試劑 | Accutase |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305730-161225 | 分析證明書 | 23. Apr. 2026 | 305730 |